Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Sanofi
- Study ID
- NCT06914908
- Phase
- PHASE2
- Status
- Enrolling By Invitation
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- lunsekimig — DRUGPharmaceutical form: solution for injection Route of administration: subcutaneous
- Mometasone furoate nasal spray (MFNS) — DRUGPharmaceutical form: Intranasal spray Route of administration: intranasal
Study Details
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up.
Key Dates
- Start date
- May 12, 2025
- Status verified
- May 2026
- Primary completion
- Jan 29, 2031
- Completion
- Jan 29, 2031
Study Design
- Enrollment
- 64 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: LunsekimigParticipant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) daily for 52 weeks.
Primary Outcome Measure
Incidence of participants with treatment-emergent adverse events (TEAEs) including [ Time Frame: From baseline to end of study (approximately 56 weeks) ]
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Modena Allergy + Asthma- Site Number : 8400005 | La Jolla | California | 92037 | - |
| Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003 | Roseville | California | 95661 | - |
| Treasure Valley Medical Research- Site Number : 8400002 | Boise | Idaho | 83706 | - |
| Essential Medical Research- Site Number : 8400020 | Tulsa | Oklahoma | 74137 | - |
| McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 | Bellaire | Texas | 77401 | - |
| Pharmaceutical Research & Consulting- Site Number : 8400004 | Dallas | Texas | 75231 | - |
| ENT Associates of Texas - McKinne- Site Number : 8400014 | McKinney | Texas | 75070 | - |
| Alamo ENT Associates- Site Number : 8400001 | San Antonio | Texas | 78258 | - |
| Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008 | Norfolk | Virginia | 23510 | - |
Find similar trials in La Jolla, CA
By research site
Modena Allergy + Asthma· La Jolla, CASacramento Ear Nose & Throat - Roseville· Roseville, CATreasure Valley Medical Research· Boise, IDEssential Medical Research· Tulsa, OKMcGovern Medical School - UT Physicians Dermatology - Bellaire Station· Bellaire, TXPharmaceutical Research & Consulting· Dallas, TX
Related Studies
- An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsPHASE3 · Enrolling By Invitation · Sanofi · La Mesa, California
- Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal PolyposisRecruiting · Montefiore Medical Center · The Bronx, New York
- The Role of IL5 in Epithelial Cell IntegrityEARLY_PHASE1 · Recruiting · Johns Hopkins University · Baltimore, Maryland
- 3D Printing to Improve Nasal Irrigation OutcomeRecruiting · Ohio State University · Columbus, Ohio